RU2633236C2 - Способы и композиции для лечения болезни рейно - Google Patents

Способы и композиции для лечения болезни рейно Download PDF

Info

Publication number
RU2633236C2
RU2633236C2 RU2013141836A RU2013141836A RU2633236C2 RU 2633236 C2 RU2633236 C2 RU 2633236C2 RU 2013141836 A RU2013141836 A RU 2013141836A RU 2013141836 A RU2013141836 A RU 2013141836A RU 2633236 C2 RU2633236 C2 RU 2633236C2
Authority
RU
Russia
Prior art keywords
composition
prostaglandin
dimethylamino
semi
affected part
Prior art date
Application number
RU2013141836A
Other languages
English (en)
Russian (ru)
Other versions
RU2013141836A (ru
Inventor
Дэниел В. ФРЭНК
Ричард Мартин
Бассам Б. ДАМАЖ
Original Assignee
Нексмед Холдингс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нексмед Холдингс, Инк. filed Critical Нексмед Холдингс, Инк.
Publication of RU2013141836A publication Critical patent/RU2013141836A/ru
Application granted granted Critical
Publication of RU2633236C2 publication Critical patent/RU2633236C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2013141836A 2011-04-07 2012-04-06 Способы и композиции для лечения болезни рейно RU2633236C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472988P 2011-04-07 2011-04-07
US61/472,988 2011-04-07
PCT/US2012/032577 WO2012139033A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating raynaud's disease

Publications (2)

Publication Number Publication Date
RU2013141836A RU2013141836A (ru) 2015-05-20
RU2633236C2 true RU2633236C2 (ru) 2017-10-11

Family

ID=46969575

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013141836A RU2633236C2 (ru) 2011-04-07 2012-04-06 Способы и композиции для лечения болезни рейно

Country Status (8)

Country Link
US (4) US8940794B2 (https=)
EP (1) EP2693877A4 (https=)
JP (1) JP2014510156A (https=)
BR (1) BR112013025744A2 (https=)
CA (1) CA2838109C (https=)
MX (1) MX342511B (https=)
RU (1) RU2633236C2 (https=)
WO (1) WO2012139033A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004227853A1 (en) 2003-04-02 2004-10-21 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
MX2015010041A (es) * 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
CN109288848A (zh) * 2018-11-27 2019-02-01 西安力邦肇新生物科技有限公司 前列腺素e1甲酯在制备扩张血管药物中的应用
US20240299413A1 (en) 2020-08-07 2024-09-12 Eicos Sciences, Inc. Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration
WO2025019625A1 (en) 2023-07-18 2025-01-23 Btg International Inc. Method of using iloprost for treating frostbite

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US20080069883A1 (en) * 2003-04-02 2008-03-20 Nexmed Holdings, Inc. Prostaglandin compositions and methods for the treatment of vasospasm
RU2342386C2 (ru) * 2002-10-30 2008-12-27 Мерк Фросст Кэнада Лтд Производные пиридопирролизина и пиридоиндолизина

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029814A (en) 1975-12-29 1977-06-14 The Upjohn Company Phenyl-substituted prostaglandin-e type analogs
US4212987A (en) 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
DE3704825A1 (de) * 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
ES2093774T3 (es) 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
US5403867A (en) 1992-02-07 1995-04-04 Kaken Pharmaceutical Co., Ltd. Preparation for treating wounds or hemorrhoids
ATE285212T1 (de) 1993-10-07 2005-01-15 Odontex Inc Absorptionsförderer für topische pharmazeutische formulierungen
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US20020165122A1 (en) 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
TW473834B (en) 1998-05-01 2002-01-21 Ibm Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
CA2442479C (en) 1999-05-13 2005-12-13 Nexmed Holdings, Inc. Topical compositions for prostaglandin e1 delivery
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105572B2 (en) 2000-02-04 2006-09-12 Takeda Pharmaceutical Company Limited Stable emulsion compositions
US20060148907A1 (en) 2002-07-24 2006-07-06 Nicholson David M Topical antinflammatory preparations of y-terpinene
US6841574B2 (en) 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
PL2084124T3 (pl) * 2006-10-02 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
EP2011496A1 (en) 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2342386C2 (ru) * 2002-10-30 2008-12-27 Мерк Фросст Кэнада Лтд Производные пиридопирролизина и пиридоиндолизина
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US20080069883A1 (en) * 2003-04-02 2008-03-20 Nexmed Holdings, Inc. Prostaglandin compositions and methods for the treatment of vasospasm

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHLEZ A. et al. Systemic scleroderma patients have improved skin perfusion after the transdermal application of PGE1 ethyl ester// Vasa. 2003 May; 32(2): 83-6, реф. Ambrosioni E. et al. The pharmacology and clinical aspects of the prostanoids// Ann Ital Med Int. 1993 Oct;8 Suppl:59S-65S, реф. Yokota S. et al. Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease// Ryumachi. 1994 Dec;34(6):955-60, реф. *
АЛЕКСЕЕВА Е.И. и др. Опыт применения алпростадила при синдроме Рейно у детей// Вопросы современной педиатрии, 2007, т.6, 5, с.128-131. *

Also Published As

Publication number Publication date
US20160331761A1 (en) 2016-11-17
US20140200274A1 (en) 2014-07-17
CA2838109A1 (en) 2012-10-11
US9855231B2 (en) 2018-01-02
US10632086B2 (en) 2020-04-28
MX2013011662A (es) 2013-12-12
RU2013141836A (ru) 2015-05-20
US9517218B2 (en) 2016-12-13
WO2012139033A1 (en) 2012-10-11
CA2838109C (en) 2020-06-09
US20160081954A1 (en) 2016-03-24
US8940794B2 (en) 2015-01-27
JP2014510156A (ja) 2014-04-24
US20180333377A1 (en) 2018-11-22
EP2693877A4 (en) 2014-11-19
BR112013025744A2 (pt) 2016-08-16
MX342511B (es) 2016-10-03
EP2693877A1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
US10632086B2 (en) Methods and compositions for treating Raynaud's disease
KR102506333B1 (ko) 아세나핀을 함유하는 경피흡수 치료 시스템
AU2003220786B2 (en) Orodispersible pharmaceutical composition comprising agomelatine
RO112991B1 (ro) Preparat tip hidrogel, cu eliberare sustinuta
Koland et al. Mucoadhesive films of losartan potassium for buccal delivery: Design and characterization
KR102802121B1 (ko) 아세나핀을 함유하는 경피 치료 시스템
HU229083B1 (en) Compositions and methods for amelioration of human female sexual dysfunction
HUE027395T2 (hu) Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással
US20100086495A1 (en) Compositions and methods for enhancing transmucosal delivery
Arndts et al. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine
Parati et al. Difference between office and ambulatory blood pressure and response to antihypertensive treatment
CN114615974B (zh) 环加氧酶抑制剂的局部制剂及其用途
JP2001199883A (ja) 消炎鎮痛外用剤
Kaleli et al. Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study
US4842854A (en) Antianginal plate for treating ischemic heart disease
US4921695A (en) Antianginal plate for treating ischemic heart disease
WO2021056109A1 (en) Gel base composition for compounding into a mucoadhesive delivery system
JP4157889B2 (ja) 性交機能改善用外用製剤
TR2022020426A2 (tr) İndometazi̇n ve famoti̇di̇n?i̇ bi̇r arada i̇çeren ağizda dağilan tablet (odt) formülasyonlari
Schäfer-Korting et al. Human plasma and skin blister fluid levels of griseofulvin after its repeated administration
US20150320764A1 (en) Treating female sexual arousal disorder and related symptoms
WO2020094251A2 (en) Treatment of portal hypertension and cirrhosis
KR102488424B1 (ko) 질내 삽입형 에스트라다이올 약제학적 조성물 및 방법
Karthik et al. FORMULATION AND EVALUTION OF TERBUTALINE SULPHATE BUCCAL PATCHES BY USING HPMC K4M, HPMC E15 POLYMERS
JPH10139687A (ja) 皮膚外用液剤